Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Third Deal In The Space Since POINT Purchase
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
